Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Cancer immunotherapies targeting immune checkpoints such as programmed cell-death protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are revolutionizing cancer treatment and transforming the practice of medical oncology. However, despite all the recent successes of this type o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chocarro de Erauso, Luisa, Zuazo, Miren, Arasanz, Hugo, Bocanegra, Ana, Hernandez, Carlos, Fernandez, Gonzalo, Garcia-Granda, Maria Jesus, Blanco, Ester, Vera, Ruth, Kochan, Grazyna, Escors, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154133/
https://www.ncbi.nlm.nih.gov/pubmed/32317979
http://dx.doi.org/10.3389/fphar.2020.00441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154133/
https://www.ncbi.nlm.nih.gov/pubmed/32317979
http://dx.doi.org/10.3389/fphar.2020.00441

Ejemplares similares